Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

计划入组 75 人 · 首次发布于 2023 年 11 月 1 日

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

计划入组 90 人 · 首次发布于 2022 年 3 月 11 日

Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

计划入组 20 人 · 首次发布于 2016 年 3 月 17 日

pUMVC3-IGFBP2-HER2-IGF1R

IGF1R inhibitors(Boehringer Ingelheim)

Advancing Pediatric Rhabdomyosarcoma Therapeutics: FGFR4, MYOD1, and Novel Degrader Strategies Take Center Stage

GSK and ABL Bio Partner on £2 Billion Deal to Overcome Blood-Brain Barrier in Neurodegenerative Disease Treatment

GSK Expands Neurodegenerative Disease Portfolio with $2.5B+ ABL Bio Partnership